Compare KINS & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KINS | BDSX |
|---|---|---|
| Founded | 1886 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 279.5M | 276.2M |
| IPO Year | 2013 | 2020 |
| Metric | KINS | BDSX |
|---|---|---|
| Price | $22.93 | $10.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $32.17 |
| AVG Volume (30 Days) | 93.7K | ★ 237.3K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.03% | N/A |
| EPS Growth | ★ 94.59 | N/A |
| EPS | ★ 1.86 | N/A |
| Revenue | ★ $214,867,301.00 | $88,499,000.00 |
| Revenue This Year | $18.83 | $18.90 |
| Revenue Next Year | $15.85 | $20.34 |
| P/E Ratio | $12.49 | ★ N/A |
| Revenue Growth | ★ 38.50 | 24.08 |
| 52 Week Low | $13.83 | $5.26 |
| 52 Week High | $23.42 | $31.97 |
| Indicator | KINS | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 67.82 | 24.51 |
| Support Level | $18.35 | $9.43 |
| Resistance Level | N/A | $16.66 |
| Average True Range (ATR) | 0.86 | 2.15 |
| MACD | 0.33 | -1.08 |
| Stochastic Oscillator | 86.05 | 14.40 |
Kingstone Companies Inc offers property and casualty insurance products through its subsidiary engaged in writing business through retail and wholesale agents and brokers. Its products include Personal lines, Livery physical damage, and Others. It operates in single segment, property and casualty insurance. It derives substantially all of its revenue from KICO, including revenues from earned premiums, ceding commissions from quota share reinsurance, net investment income generated from its investment portfolio, and net realized gains and losses on investment securities.
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.